Research Analysts Set Expectations for TLX FY2026 Earnings

Telix Pharmaceuticals Limited (NASDAQ:TLX) – Stock analysts at William Blair decreased their FY2026 earnings per share (EPS) estimates for shares of Telix Pharmaceuticals in a research note issued on Thursday, August 28th. William Blair analyst A. Hsieh now anticipates that the company will post earnings per share of $0.15 for the year, down from their prior forecast of $0.28. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.24 per share.

TLX has been the subject of a number of other reports. HC Wainwright started coverage on shares of Telix Pharmaceuticals in a report on Thursday, July 3rd. They set a “buy” rating and a $23.00 price objective for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. Finally, Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $22.33.

Telix Pharmaceuticals Stock Performance

Shares of TLX stock opened at $9.55 on Monday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78. The firm has a fifty day simple moving average of $13.78 and a two-hundred day simple moving average of $15.98. Telix Pharmaceuticals has a 12 month low of $9.48 and a 12 month high of $30.36.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC bought a new position in shares of Telix Pharmaceuticals during the 1st quarter worth approximately $170,000. IHT Wealth Management LLC bought a new position in shares of Telix Pharmaceuticals in the second quarter valued at approximately $213,000. Blair William & Co. IL purchased a new stake in shares of Telix Pharmaceuticals during the second quarter valued at approximately $217,000. Vanguard Personalized Indexing Management LLC bought a new stake in Telix Pharmaceuticals during the second quarter worth $297,000. Finally, ABC Arbitrage SA purchased a new position in Telix Pharmaceuticals in the first quarter worth $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.